Jefferies initiated coverage of aTyr Pharma with a Buy rating and $9 price target. Efzofitimod is a “first-in-class” tRNA synthatase-derived therapy that has demonstrated clinical proof of concept in pulmonary sarcoidosis, the analyst tells investors in a research note. The firm says the ongoing Phase 3 will report in Q3 of 2025 and potentially support the first drug approval in pulmonary sarcoidosis, if successful.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma to Participate in September Investor Conferences
- aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma reports Q2 EPS (23c), consensus (24c)
- LIFE Upcoming Earnings Report: What to Expect?
- aTyr Pharma appoints Jayant Aphale as VP, technical operations